English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Isorhamnetin (Iso) exhibits antitumor effects in promyelotic leukemia and lung cancers. However, its effect in liver cancer is not clear. This study explored the effects of Iso in human liver cancer cells and profiled the differential proteins upon Iso treatment, which contributes to a better understanding of its anticancer mechanisms. Stable isotope labeling with amino acids in cell culture-mass spectrometry: ESI-Iontrap (SILAC-MS) was used to study the differentially proteomic profile of Iso-treated HepG2 cells. Iso inhibits HepG2 cell proliferation in a dose-dependent manner.  A total of 84 proteins are identified, among which 7 proteins were up-regulated while 77 proteins were down-regulated. Iso inhibits HepG2 cell proliferation by the induction of apoptosis and the inhibition of protein synthesis of human liver cancer cell.   Key words:  Isorhamnetin, Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC), differential proteomic profile, HepG2 cells.

Quantitative proteomic analysis of Isorhamnetin treatment in human liver cancer cells